<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03190525</url>
  </required_header>
  <id_info>
    <org_study_id>QoL-MM1016</org_study_id>
    <nct_id>NCT03190525</nct_id>
  </id_info>
  <brief_title>Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma</brief_title>
  <acronym>CLARITY</acronym>
  <official_title>CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC
      QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life
      Questionnaire-Core 30) fatigue scale ratings, independently from other prognostic factors for
      OS in multiple myeloma (MM), including the clinically-based prognostic frailty score.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While quality of life (QoL) and other types of patient-reported Outcomes (PROs) can be
      crucial in the management of RRMM patients, a perusal of the literature indicates a dearth of
      information in this area. PRO is defined by the US Food and Drug Administration (FDA) as &quot;a
      measurement based on a report that comes directly from the patient (i.e., study subject)
      about the status of a patient's health condition without amendment or interpretation of the
      patient's response by a clinician or anyone else. A PRO can be measured by self-report or by
      interview provided that the interviewer records only the patient's response. Until now the
      few studies that have included PRO data have been conducted in newly diagnosed MM patients
      enrolled in randomized controlled trials (RCTs).

      For the purpose of this protocol, we have conducted a systematic review of PRO studies
      conducted in RRMM patients receiving treatments with either Imunomodulatory agents (IMiDs) or
      Proteasome inhibitors (PIs). The search was conducted for studies published from January,
      1990 to July, 2015 and yielded only eight studies published within this timeframe. Three
      studies dealt with bortezomib based regimens, two with thalidomide, and the remaining studies
      with carfilzomib, pomalidomide, and lenalidomide. In all these studies PROs were considered
      as secondary outcomes and in four this was analyzed in the context of RCTs.

      Despite enhanced disease control, none of the current novel agents, either IMiDs or PIs are
      free of significant toxicities, which frequently persist after completing treatment and
      continue to impair patient's daily functioning over the long-term period. Also, it is
      important to consider the poor prognosis for many of these patients. For example, patients
      who fail first-line PIs or IMiDs have been shown to report an average life expectancy of 9
      months from the time of becoming refractory to PIs and IMiDs. Maintaining a &quot;good&quot; or
      &quot;acceptable&quot; level of QoL and lowering symptom burden over the longest possible period of
      time is a main goal of treatment for RRMM patients. Therefore, considering the paucity of QoL
      evidence-base data, CLARITY is designed to expand on some key understudied areas in this
      population that are broadly summarized in the next two paragraphs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.</measure>
    <time_frame>30 months from study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To devise a patient-centered frailty score for RRMM patients.</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the prognostic value of the frailty score in the setting of RRMM.</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate QoL over time (outcome measures: EORTC QLQ-C30 and QLQ-MY20) by type of treatment and examine factors that contribute the most in maintaining baseline QoL levels.</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate relationship between satisfaction with information provision (outcome measure: EORTC INFO-25) and QoL outcomes (outcome measures: EORTC QLQ-C30 and QLQ-MY20).</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess patients' preferences for involvement in treatment decision-making and the relationships between preferences and patient characteristics.</measure>
    <time_frame>30 months from study entry</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Multiple Myeloma patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life questionnaires</intervention_name>
    <description>QLQ-C30</description>
    <arm_group_label>Multiple Myeloma patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Considering the observational nature of study and fact that we aim to provide data on RRMM
        patients from the real-world setting, we have set up very broad inclusion criteria.
        Patients enrolled in clinical trials are still eligible for this protocol. Possible
        participation in a clinical trial at the time of entry in this study will be recorded and
        used for sensitivity analysis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MM patients who have received at least 1 prior line of therapy and are considered as
             RRMM according to IMWG criteria.

          -  Adult patients (≥ 18 years old).

          -  Written informed consent provided.

          -  Patients who have been enrolled onto other study therapy protocols are also eligible.

          -  Having a full baseline PRO evaluation completed.

          -  All data a available to calculate the frailty score.

        Exclusion Criteria:

          -  Having any kind of psychiatric disorder or major cognitive dysfunction hampering the
             provision of informed consent.

          -  Having reported any grade ≥3 adverse event within two weeks prior to study entry.

          -  Having received more than 5 lines of therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Fabio Efficace</last_name>
    <role>Study Chair</role>
    <affiliation>GIMEMA Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Cavo</last_name>
    <role>Study Director</role>
    <affiliation>S. Orsola Malpighi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesca Tartaglia</last_name>
    <phone>+39 06.70390521</phone>
    <email>f.tartaglia@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michela Servadio</last_name>
    <phone>+39 06441639837</phone>
    <email>m.servadio@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale G1 Regionale Generale &quot;F.Miulli&quot;</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Polimeno</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Polimeno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Offidani</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Offidani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Cavo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Pastore</last_name>
    </contact>
    <investigator>
      <last_name>Domenico Pastore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniele Derudas</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Derudas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CTMO - Ematologia - Ospedale &quot;Binaghi&quot;</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Caocci</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Caocci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Ledda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - Ospedale S.Elia</name>
      <address>
        <city>Caltanissetta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Rizzo</last_name>
    </contact>
    <investigator>
      <last_name>Michele Rizzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Onco-Ematologia - A.O. S.Anna e S.Sebastiano</name>
      <address>
        <city>Caserta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Camera</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Camera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità di Onco-Ematologia - Azienda Ospedaliera - Garibaldi</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ugo Consoli</last_name>
    </contact>
    <investigator>
      <last_name>Ugo Consoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Di Raimondo</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Molica</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Molica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gian Matteo Rigolin</last_name>
    </contact>
    <investigator>
      <last_name>Gian Matteo Rigolin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Gentile</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Gentile</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Bosi</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Reddiconto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Un.Op. di Medicina Generale Ospedale di Matera</name>
      <address>
        <city>Matera</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Fragasso</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Fragasso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Musolino</last_name>
    </contact>
    <investigator>
      <last_name>Caterina Musolino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Mannina</last_name>
    </contact>
    <investigator>
      <last_name>Donato Mannina</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santo Neri</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia- Ospedale dell'Angelo - Mestre</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renato Bassan</last_name>
    </contact>
    <investigator>
      <last_name>Renato Bassan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Potenza</last_name>
    </contact>
    <investigator>
      <last_name>Leonardo Potenza</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanna Leonardi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorella Depaoli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncoematologia -plesso ospedaliero &quot;A. Tortora&quot; di Pagani</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catello Califano</last_name>
    </contact>
    <investigator>
      <last_name>Catello Califano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Lucia Barone</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Siragusa</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Siragusa</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melania Carlisi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Day Hospital dell'U.O.C di Ematologia e CTMO Padiglione 1 TORRE DELLE MEDICINE, 6° piano</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Petrini</last_name>
    </contact>
    <investigator>
      <last_name>Mario Petrini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriele Buda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Pizzuti</last_name>
    </contact>
    <investigator>
      <last_name>Michele Pizzuti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Immacolata Attolico</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOS di Ematologia Servizio di Immunoematologia e medicina Trasfusionale Azienda Sanitaria Provinciale 7</name>
      <address>
        <city>Ragusa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Cabibbo</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Cabibbo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agostino Antolino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Gamberi</last_name>
    </contact>
    <investigator>
      <last_name>Barbara Gamberi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micol Quaresima</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizia Tosi</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Tosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Lia Molinari</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia - Centro Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni D'Arena</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni D'Arena</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanna Manuseto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agostino Tafuri</last_name>
    </contact>
    <investigator>
      <last_name>Agostino Tafuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giacinto La Verde</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia - Università Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ombretta Annibali</last_name>
    </contact>
    <investigator>
      <last_name>Ombretta Annibali</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeria Tomarchio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S. Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Teresa Petrucci</last_name>
    </contact>
    <investigator>
      <last_name>Maria Teresa Petrucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Grammatico</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi - Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Cantonetti</last_name>
    </contact>
    <investigator>
      <last_name>Maria Cantonetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Franceschini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Medicina Trasfusionale e Cellule Staminali Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncologia - Presidio Ospedaliero N. Giannetasio - Azienda ASL 3</name>
      <address>
        <city>Rossano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Iuliano</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Iuliano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Aquila Santoro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonieta Pia Falcone</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Fozza</last_name>
    </contact>
    <investigator>
      <last_name>Claudio Fozza</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigi Podda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Gozzetti</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Gozzetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Candi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Ematolgia - A.O. &quot; SS Annunziata&quot; - P.O. S.G. Moscati</name>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizio Mazza</last_name>
    </contact>
    <investigator>
      <last_name>Patrizio Mazza</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Amurri</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati</last_name>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Lombardo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell' Università degli Studi di Torino - &quot;Città della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Boccadoro</last_name>
    </contact>
    <investigator>
      <last_name>Mario Boccadoro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa II Medicina - Ematologia - Centro di Riferimento Ematologico - Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Vidus</last_name>
    </contact>
    <investigator>
      <last_name>Marta Vidus</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Desabbata</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS N.6 Osp. S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Ruggeri</last_name>
    </contact>
    <investigator>
      <last_name>Marco Ruggeri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

